Author(s): Nandini Singh, Amresh Kumar Singh, Ashwini Kumar Mishra, Narendra Pratap Singh, Sushil Kumar

Email(s): sushilk731@gmail.com

DOI: 10.52711/0974-360X.2024.00204   

Address: Nandini Singh1, Amresh Kumar Singh2, Ashwini Kumar Mishra3, Narendra Pratap Singh4, Sushil Kumar5*
1Research Scholar, Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India – 273009.
2Associate Professor, Head/Incharge COVID-19 Laboratory, Department of Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh - 273013, India.
3Associate Professor, Department of Tuberculosis and Chest, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh - 273013, India.
4Lab microbiologist, Department of Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh - 273013, India.
5Assistant Professor, Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India – 273009.
*Corresponding Author

Published In:   Volume - 17,      Issue - 3,     Year - 2024


ABSTRACT:
Globally, drug-resistant tuberculosis is major public health issue. Multidrug-resistant tuberculosis (MDR-TB), especially resistant to first line drugs (isoniazid [INH] and rifampicin [RMP]), is one of the serious health concerns in India. As per annual India TB report 2022, 2.7% of total TB patients were infected with MDR-TB. Line probe assay (LPA)/GenoTypeMTBDRplus technique based on polymerase chain reaction is a rapid method for the detection of RMP and INH simultaneously. This cross-sectional prospective study includes 405 samples from suspected TB patients from 30.12.2021 to 13.05.2022. Samples were received from linked districts with Intermediate Reference Laboratory (IRL) for fluorescent microscopy (FM) and LPA testing through proper cold-chain under NTEP program and then subjected to FM. Only smear positive sample were subjected to LPA as per manufacturer instructions. Out of 405, a total of 261 samples were smear positive (64.4%). Among 261 samples processed for LPA, 255(97.7%) showed valid result and 6(2.3%) were found invalid. In LPA result, 227 (89.01%) were susceptible to both INH and RMP, 9(3.5%) had MDR-TB, 18(7.05%) shows INH mono resistance and 1(0.3%) shows RMP mono resistance. Patients with MDR-TB were prominent in younger age group (Mean±S.D; 29.6±5.7 vs. 36.6±17.8 years, p value = 0.004). Prevalence of MDR-TB cases is higher in our study than cases reported in annual TB report (2022) of India. LPA is proved highly accurate in rapid detection RMP resistant/MDR-TB cases. Early diagnosis may potentially enable earlier commencement of appropriate TB drugs and the reduction of transmission of MDR-TB and may possibly leading to the complete eradication of TB in India.


Cite this article:
Nandini Singh, Amresh Kumar Singh, Ashwini Kumar Mishra, Narendra Pratap Singh, Sushil Kumar. Estimation of First Line Anti-Tubercular Drugs resistance and their genetic analysis by Geno Type MTBDRplus assay from an Intermediate Reference Laboratory in Eastern Uttar Pradesh, India. Research Journal of Pharmacy and Technology. 2024; 17(3):1303-7. doi: 10.52711/0974-360X.2024.00204

Cite(Electronic):
Nandini Singh, Amresh Kumar Singh, Ashwini Kumar Mishra, Narendra Pratap Singh, Sushil Kumar. Estimation of First Line Anti-Tubercular Drugs resistance and their genetic analysis by Geno Type MTBDRplus assay from an Intermediate Reference Laboratory in Eastern Uttar Pradesh, India. Research Journal of Pharmacy and Technology. 2024; 17(3):1303-7. doi: 10.52711/0974-360X.2024.00204   Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-3-55


REFERENCE:
1.    Singh L, Grower M and Vandali V. A Study to assess the Knowledge Regarding Pulmonary Tuberculosis among Family Members in Selected Rural area, Sri Ganaganagar District, Rajasthan. Int. J. Nur. Edu. and Research. 2017; 5(4): 381-384. doi: 10.5958/2454-2660.2017.00080.1.
2.    Kapadiya MN. Tuberculosis Case Study. Int. J. of Advances in Nur. Management. 2021; 9(2): 160-161. doi: 10.5958/2454-2652.2021.00036.6.
3.    Fatima N, Gangwar K, Varshey R, Pal N, Yadav S, and Sahu D. Knowledge on Prevention of Pulmonary Tuberculosis Patients among the Family Members of Patients who are Admitted in Selected Hospital in Bareilly, Uttar Pradesh with Self Instructional Module. Int. J. Nur. Edu. and Research. 2020; 8(4): 512-516. doi: 10.5958/2454-2660.2020.00114.3.
4.    Sagavkar Sandhyarani R, Devkar Swati R. Tuberculosis: A Review. Asian J. Pharm. Res. 2018; 8(3): 191-194.
5.    Tuberculosis deaths and disease increase during the COVID-19 pandemic (2022), https://www.who.int/ news/ item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic.
6.    TB incidence (2022), https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-1-tb-incidence.
7.    Kumar L, Rajan, Sharma V. Tuberculosis: A Brief Overview. Asian J. Pharm. Res. 2012; 2(2): 59-62.
8.    Annual TB Report 2022, India (2022), https://tbcindia.gov.in/WriteReadData/India%20TB%20Report% 202019.pdf.
9.    Zine S, Patankar SA, Raopati SS. Rise of Antibiotic Resistance in Tuberculosis. Research J. Pharm. and Tech. 2018; 11(7): 3201-3204. doi: 10.5958/0974-360X.2018.00588.7.
10.    Singh AK, Maurya AK, Kumar M, Kant S, Kushwaha RAS, Nag VL, and Dhole TN. Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience. J. Microbiol. Infect. Dis 2013; 3(4): 169-175. doi: 10.5799/jmid2013.04.0103.
11.    Line probe assays for detection of drug-resistant tuberculosis (2022), file:///C:/Users/cdst/Downloads /9789240046665- eng%20(1).pdf .
12.    Singh N, Singh AK, Kumar S, Singh NP, Gaur V. Role of Mycobacterial Culture and Drug Sensitivity Testing Laboratory under National Tuberculosis Elimination Program for the Abolition of Tuberculosis in India by 2025. J. Clin. Diagn. Res. 2022; 16(7)., DE1-DE5. doi: 10.7860/JCDR/2022/55426.0000.
13.    MGIT TM Procedure Manual (2006), https://www.finddx.org/wp-content/uploads/2023/02/_rep_ mgit_manual _FV_EN.pdf .
14.    GenoType MTBDRplus VER 2.0 (2015), https://www.hain-lifescience.de/includedatei/kundenmodule /packungsbeilage/ download.php?id=936.
15.    Maurya AK, Umrao J, Singh AK, Kant S, Kushwaha RA, Dhole TN. Evaluation of GenoType® MTBDRplus assay for rapid detection of drug susceptibility testing of multi-drug resistance tuberculosis in Northern India. Indian. J. Pathol. Microbiol. 2013; 56(2): 139. doi: 10.4103/0377-4929.118681.
16.    Sharma M, Kumar D, Bohra GK, Meena DS, Bhambu SK. Study of the prevalence of Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB) in Western Rajasthan using line probe assay. J Family Med Prim Care. 2020; 9(2): 1093-1097. doi:10.4103/jfmpc.jfmpc_916_19.
17.    Singla N, Satyanarayana S, Sachdeva KS, Van den Bergh R, Reid T, Tayler-Smith K, Myneedu VP, Ali E, Enarson DA, Behera D, Sarin R. Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India. PLoS One. 2014; 9(7): e102989.  doi:10.1371/journal.pone.0102989.
18.    Rashid O, Farhana A, Bali N, Peer M, Kour R, Nasir R, Bashir Y. Early Detection of Multi-drug Resistant Tuberculosis and Mutations in Mycobacterium tuberculosis Isolates using Line Probe Assay from a Tertiary Care Centre in Northern India. J. Clin. Diagn. Res. 2020; 14(6).
19.    Mohan S, Pujari V, Meshram P. Drug resistance patterns and treatment outcomes in DR-TB patients at a tertiary care centre in Mumbai. Indian. J. Tuberc.. 2023. https://doi.org/10.1016/j.ijtb.2023.01.006.
20.    Palani N, Premkumar M, Vaishnavee V, Dinesh V, Thiruvengadam K, Lavanya J, Sridhar R, Frederick A, Sivaramakrishnan G, Mondal R, Padmapriyadarsini C. Trends in rifampicin and isoniazid resistance in patients with presumptive TB. Int. J. Tuberc. Lung Dis. 2022; 26(5): 446-53. doi: https://doi.org/10.5588/ijtld.21.0455.
21.    Prasad PG, Jasmine MS, Deepthi K, Allam US. Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India. Braz. J. Infect. Dis. 2019; 23: 281-90. doi: https://doi.org/10.1016/j.bjid.2019.07.002.
22.    Shivekar SS, Kaliaperumal V, Brammacharry U, Sakkaravarthy A, Raj CV, Alagappan C, Muthaiah M. Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Scientific reports. 2020; 10(1): 17552. doi:https://doi.org/10.1038/s41598-020-74432-y.
23.    Singhal R, Arora J, Sah GC, Bhalla M, Sarin R, Myneedu VP. Frequency of multi-drug resistance and mutations in Mycobacterium tuberculosis isolates from Punjab state of India. J. Epidemiol. Glob. Health. 2017; 7(3): 175-80. doi: https://doi.org/10.1016/j.jegh.2017.05.002.
24.    Desikan P, Kharate A, Panwalkar N, Khurana J, Mirza SB, Chaturvedi A, Varathe R, Chourey M, Kumar P, Doshi N, Pandey M. Frequency of mutations in rifampicin and isoniazid resistant isolates of M. tuberculosis: an analysis from Central India. Germs. 2016; 6(4): 125. doi: 10.11599/germs.2016.1096.
25.    Tripathi R, Anupurba S. Multidrug-resistant tuberculosis detection and characterization of mutations in mycobacterium tuberculosis by genotype MTBDRplus. Indian J. Pathol. Microbiol. 2017; 60(2): 239. doi: 10.4103/IJPM.IJPM_53_16.
26.    Jain A, Singh PK, Chooramani G, Dixit P, Malhotra HS. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India. Int. J. Tuberc. Lung Dis 2016; 20(7): 870-5. doi: https://doi.org/10.5588/ijtld.15.0874.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available